A Systematic Review of Medical Treatments for Children With Autism Spectrum Disorders
The DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.
Abstract
CONTEXT: As many as 1 in every 110 children in the United States has an autism spectrum disorder (ASD). Many medical treatments for ASDs have been proposed and studied, but there is currently no consensus regarding which interventions are most effective. OBJECTIVE: To systematically review evidence regarding medical treatments for children aged 12 years and younger with ASDs. METHODS: We searched the Medline, PsycInfo, and ERIC (Education Resources Information Center) databases from 2000 to May 2010, regulatory data for approved medications, and reference lists of included articles. Two reviewers independently assessed each study against predetermined inclusion/exclusion criteria. Studies of secretin were not included in this review. Two reviewers independently extracted data regarding participant and intervention characteristics, assessment techniques, and outcomes and assigned overall quality and strength-of-evidence ratings on the basis of predetermined criteria. RESULTS: Evidence supports the benefit of risperidone and aripiprazole for challenging and repetitive behaviors in children with ASDs. Evidence also supports significant adverse effects of these medications. Insufficient strength of evidence is present to evaluate the benefits or adverse effects for any other medical treatments for ASDs, including serotonin-reuptake inhibitors and stimulant medications. CONCLUSIONS: Although many children with ASDs are currently treated with medical interventions, strikingly little evidence exists to support benefit for most treatments. Risperidone and aripiprazole have shown benefit for challenging and repetitive behaviors, but associated adverse effects limit their use to patients with severe impairment or risk of injury.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“citalopram has demonstrated poor tolerability and no benefit for repetitive behaviour in children with ASD 208 .”
From Autism spectrum disorder (2020) · cites this paper as [208]
In the citing paper
“Although these drugs serve to manage challenging and repetitive behaviors, they have little effect on the social communication deficit observed in ASD 88 .”
From Progress toward treatments for synaptic defects in autism (2013) · cites this paper as [88]
In the citing paper
“These two agents, Risperdal and Abilify (11), do not target the core symptoms, but rather treat a cluster of associated symptoms referred to as irritability.”
From Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism (2012) · cites this paper as [11]
In the citing paper
“Therefore, therapeutic efficacy is currently evaluated by improvement in the diagnostic behavioral symptoms (11, 50, 95).”
From Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism (2012) · cites this paper as [11]
In the citing paper
“Dysfunction in the dopamine system in ASD has been suggested, based on the beneficial effects of dopamine receptor antagonists (for example, antipsychotic drugs such as risperidone) in treating certain symptoms commonly exhibited by affected individuals, such as stereotypies, aggression, hyperactivity, and self-injury [123].”
From Social “wanting” dysfunction in autism: neurobiological underpinnings and treatment implications (2012) · cites this paper as [123]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Diagnostic and Statistical Manual of Mental Disorders.
Widiger, T. A. (2000) · Encyclopedia of Psychology, Vol. 3. · doi:10.1037/10518-009 · Cited by 19,744
Lord, C., Rutter, M., & Le Couteur, A. (1994) · Journal of Autism and Developmental Disorders · doi:10.1007/bf02172145 · Cited by 9,065
Lord, C., Risi, S., Lambrecht, L., Cook, E. H., Leventhal, B. L., DiLavore, P. C., Pickles, A., & Rutter, M. (2000) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1005592401947 · Cited by 7,520
Risperidone in Children with Autism and Serious Behavioral Problems
McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013171 · Cited by 1,574
Educating Children with Autism
Lord, C. (2001) · Cited by 1,499
Cognitive Behavioral Therapy, Sertraline, or a Combination in Childhood Anxiety
Walkup, J. T., Albano, A. M., Piacentini, J., Birmaher, B., Compton, S. N., Sherrill, J. T., Ginsburg, G. S., Rynn, M. A., McCracken, J., Waslick, B., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804633 · Cited by 1,442
Management of Children With Autism Spectrum Disorders
Myers, S. M., Johnson, C. P., & the Council on Children With Disabilities (2007) · Pediatrics · doi:10.1542/peds.2007-2362 · Cited by 1,125
Cited by
Items 101–200 of 355
Aggression in fragile X syndrome
Wheeler, A. C., Raspa, M., Bishop, E., & Bailey, D. B. (2016) · Journal of Intellectual Disability Research · doi:10.1111/jir.12238 · Cited by 51
Child and Youth Mental Disorders: Prevalence and Evidence-Based Interventions
Waddell, C., Shepherd, C. A., Schwartz, C. R., & Barican, J. (2014) · Cited by 83
A Survey of Parents with Children on the Autism Spectrum: Experience with Services and Treatments
Becerra, T. A., Massolo, M. L., Yau, V. M., Owen-Smith, A. A., Lynch, F. L., Crawford, P. M., Pearson, K. A., Pomichowski, M. E., Quinn, V. P., Yoshida, C. K., et al. (2017) · The Permanente Journal · doi:10.7812/tpp/16-009 · Cited by 49
Complementary and alternative medicine for autism spectrum disorders: Rationale, safety and efficacy
Whitehouse, A. J. (2013) · Journal of Paediatrics and Child Health · doi:10.1111/jpc.12242 · Cited by 48
Therapeutic Effect of a Synthetic RORα/γ Agonist in an Animal Model of Autism
Wang, Y., Billon, C., Walker, J. K., & Burris, T. P. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00159 · Cited by 53
Juarez-Martinez, E. L., Sprengers, J. J., Cristian, G., Oranje, B., van Andel, D. M., Avramiea, A.-E., Simpraga, S., Houtman, S. J., Hardstone, R., Gerver, C., et al. (2023) · Biological Psychiatry: Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2021.08.009 · Cited by 48
7,8-Dihydroxyflavone as a pro-neurotrophic treatment for neurodevelopmental disorders
Du, X., & Hill, R. (2015) · Neurochemistry International · doi:10.1016/j.neuint.2015.07.021 · Cited by 52
Nakai, N., Takumi, T., Nakai, J., & Sato, M. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00412 · Cited by 52
Pioglitazone abolishes autistic-like behaviors via the IL-6 pathway
Kirsten, T. B., Casarin, R. C. V., Bernardi, M. M., & Felício, L. F. (2018) · PLoS ONE · doi:10.1371/journal.pone.0197060 · Cited by 48
Understanding autism: Causes, diagnosis, and advancing therapies
Wang, M., Zhang, X., Zhong, L., Zeng, L., Li, L., & Yao, P. (2025) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2025.111411 · Cited by 79
“Clinicians often prescribe psychostimulants, antipsychotics, antidepressants, and medications for sleep disorders based on comorbidities such as emotional dysregulation or ADHD, to improve the patient ’ s quality of life (McPheeters et al., 2011).”
Integrative Approaches to Caring for Children with Autism
Klein, N., & Kemper, K. J. (2016) · Current problems in pediatric and adolescent health care · doi:10.1016/j.cppeds.2015.12.004 · Cited by 63
“Multiple RCTs have failed to demonstrate effectiveness of secretin in improving ASD-related symptoms.(41) Due to the lack of evidence of effectiveness and the substantial costs and/or risks, clinicians should avoid or discourage use of hyperbaric oxygen, chelation, or secretin therapy for ASD-related symptoms.”
BackgroundLi, Y., Li, Y., & Xiang, D.-X. (2017) · European Journal of Nutrition · doi:10.1007/s00394-017-1528-6 · Cited by 53
Wang, S., Chen, D., Yang, Y., Zhu, L., Xiong, X., & Chen, A. (2023) · Autism Research · doi:10.1002/aur.3004 · Cited by 61
“At present, the mainstream intervention methods for ASD are generally divided into two categories, one is drug therapy (McPheeters et al., 2011) and the other is behavioral intervention.”
BackgroundOxotremorine treatment reduces repetitive behaviors in BTBR T+ tf/J mice
Amodeo, D. A., Yi, J., Sweeney, J. A., & Ragozzino, M. E. (2014) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2014.00017 · Cited by 50
“, Talati, R., and Ragozzino, M. E. (2008). Differential involvement of M1-type and M4-type muscarinic cholinergic receptors in the”
Targeted treatments in autism and fragile X syndrome
Gürkan, C. K., & Hagerman, R. J. (2012) · Research in Autism Spectrum Disorders · doi:10.1016/j.rasd.2012.05.007 · Cited by 44
Zhang, L., Weitlauf, A. S., Amat, A. Z., Swanson, A. R., Warren, Z. E., & Sarkar, N. (2019) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-019-04246-z · Cited by 60
“Although a growing body of literature indicates that behavioral and pharmacological interventions have some benefits for many children with ASD (McPheeters et al. 2011; VeenstraVanderWeele and Warren 2015; Weitlauf et al. 2014), the generalizability and impact of this work has been hampered by a lack of pragmatic outc…”
BackgroundSelf-citationDalwai, S. H., Ahmed, S., Udani, V. P., Mundkur, N., Kamath, S. S., & Nair, M. K. C. (2017) · Indian Pediatrics · doi:10.1007/s13312-017-1112-4 · Cited by 47
“The available evidence suggests that fluoxetine may be beneficial for repetitive behaviors and rigidity [60].”
BackgroundDetection of Autism Spectrum Disorder by Discriminant Analysis Algorithm
Nishat, M. M., Faisal, F., Hasan, T., Nasrullah, S. M., Bristy, A. H., Shawon, M. M. I., & Hoque, M. A. (2021) · Lecture notes on data engineering and communications technologies · doi:10.1007/978-981-16-6636-0_36 · Cited by 43
Influence of stimulant-induced hyperactivity on social approach in the BTBR mouse model of autism
Silverman, J. L., Babineau, B. A., Oliver, C. F., Karras, M. N., & Crawley, J. N. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.07.042 · Cited by 42
“Translational research is needed to discover pharmacological targets for the diagnostic domains (McPheeters et al., 2011; Veenstra-VanderWeele and Blakely, 2012; Wink et al., 2010).”
Antipurinergic therapy for autism—An in-depth review
Naviaux, R. K. (2017) · Mitochondrion · doi:10.1016/j.mito.2017.12.007 · Cited by 43
“In over 20 years of modern clinical trial efforts (McPheeters et al., 2011) and 75 years since the first description of autism (Kanner, 1943), no drug has been FDA approved to treat the core symptoms of autism spectrum disorder (ASD).”
BackgroundCouteur, A. S. L., & Szatmári, P. (2015) · Wiley eBooks · doi:10.1002/9781118381953.ch51 · Cited by 58
Psychotropic Polypharmacy Among Children and Youth with Autism: A Systematic Review
Ritter, C., Hewitt, K., & McMorris, C. A. (2021) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2020.0110 · Cited by 45
“…that youth with autism currently experience when using psychotropic medications, including adverse drug reactions such as marked weight gain, sedation, and the risk of extrapyramidal symptoms (e.g., tremors, dystonia, paranoia; Aman et al. 2005; McDougle et al. 2005; McPheeters et al. 2011).”
Foss‐Feig, J. H., McPartland, J. C., Anticevic, A., & Wolf, J. M. (2015) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-015-2539-x · Cited by 45
“For example, some medications are effective in treating stereotyped behaviors (a positive feature; McPheeters et al. 2011), whereas other novel approaches, such as oxytocin, aim to increase social approach (decrease a negative feature; Andari et al. 2010).”
Comorbid Behavioral Problems and Psychiatric Disorders in Autism Spectrum Disorders
Belardinelli, C., & Raza, M. (2016) · Journal of Childhood & Developmental Disorders · doi:10.4172/2472-1786.100019 · Cited by 38
Hyperbaric oxygen therapy for people with autism spectrum disorder (ASD)
Xiong, T., Chen, H., Luo, R., & Mu, D. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010922.pub2 · Cited by 43
Pediatric Traumatic Brain Injury and Autism: Elucidating Shared Mechanisms
Singh, R. S., Turner, R. C., Nguyen, L., Motwani, K., Swatek, M., & Lucke-Wold, B. P. (2016) · Behavioural Neurology · doi:10.1155/2016/8781725 · Cited by 45
Chun, T. H., Mace, S. E., Katz, E. R., Shook, J. E., Chun, T. H., Conners, G. P., Conway, E. E., Dudley, N. C., Fuchs, S. M., Lane, N., et al. (2016) · PEDIATRICS · doi:10.1542/peds.2016-1573 · Cited by 38
New directions in the treatment of autism spectrum disorders from animal model research
Chadman, K. K., Guariglia, S. R., & Yoo, J. H. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.678828 · Cited by 35
“Risperidone does not affect social behavior or the communication impairments, but has been shown to improve the repetitive behaviors in ASD [4,16,17].”
BackgroundShepherd, D., Landon, J., & Goedeke, S. (2017) · Autism · doi:10.1177/1362361316688869 · Cited by 41
“Note that medical treatments for ASD are not common in New Zealand, likely due to the lack of clinical evidence (McPheeters et al., 2011), and may explain the low helpfulness ratings that general practitioners receive in this country (Searing et al.”
BackgroundWong, A. Y. S., Hsia, Y., Chan, E. W., Murphy, D. G. M., Simonoff, E., Buitelaar, J. K., & Wong, I. C. K. (2014) · Autism Research · doi:10.1002/aur.1391 · Cited by 31
“Despite insufficient evidence on the efficacy and longterm safety of psychotropic drugs for ASD treatment, various medications have been used for ASD comorbidity treatment in clinical practice such as α-adrenergic agents, β-blockers, mood stabilizers, antiepileptic medication, and antipsychotics [Hollander, Phillips,…”
BackgroundMethodSun, X. (2020) · International Journal of Developmental Disabilities · doi:10.1080/20473869.2020.1793650 · Cited by 38
“2018), play-based intervention (Grant 2017), and medical treatment (McPheeters et al. 2011).”
BackgroundVause, T. C., Jaksic, H., Neil, N. M., Frijters, J. C., Jackiewicz, G., & Feldman, M. A. (2018) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-018-3772-x · Cited by 36
Intellectual Disabilities and Mental Health: United States–Based Research
Charlot, L., & Beasley, J. B. (2013) · Journal of Mental Health Research in Intellectual Disabilities · doi:10.1080/19315864.2012.715724 · Cited by 37
“McPheeters et al. (2011) provided a comprehensive review of medical treatments for children with ASD covering a range of therapies.”
BackgroundJohnstone, A. L., Reierson, G. W., Smith, R. P., Goldberg, J. L., Lemmon, V., & Bixby, J. L. (2012) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2012.04.008 · Cited by 34
“Similar considerations apply to other neurodevelopmental disorders for which antipsychotics are used, including autism and depression (McPheeters et al., 2011; Pae et al., 2011).”
BackgroundLack of effect of risperidone on core autistic symptoms: data from a longitudinal study
Marrus, N., Underwood-Riordan, H., Randall, F., Zhang, Y., & Constantino, J. N. (2014) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2014.0055 · Cited by 29
“Only a minority of parents reported improvements in symptoms related to core features, with decreased rigidity/perseveration being more commonly reported than improved social competency, a finding also supported in reviews of current literature (McPheeters et al. 2011).”
Masi, A., Lampit, A., DeMayo, M. M., Glozier, N., Hickie, I. B., & Guastella, A. J. (2017) · Psychological Medicine · doi:10.1017/s0033291716003457 · Cited by 46
“The efficacy, safety and tolerability of prescription medications, some prescribed off-label for symptoms associated with ASD, have been the subject of numerous reviews (Jesner et al. 2007; McPheeters et al. 2011; Carrasco et al. 2012; Ching & Pringsheim, 2012; Hurwitz et al. 2012; Williams et al. 2013; Guastella & Hi…”
BackgroundGjevik, E., Sandstad, B., Andreassen, O. A., Myhre, A. M., & Sponheim, E. (2014) · Autism · doi:10.1177/1362361314526003 · Cited by 34
“, 2007), and antipsychotics are shown to have effect on behavioral problems (McPheeters et al., 2011).”
BackgroundThe Need for a Developmentally Based Measure of Social Communication Skills
Bishop, S. L., Farmer, C., Kaat, A. J., Georgiades, S., Kanne, S. M., & Thurm, A. E. (2019) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2018.12.010 · Cited by 37
Douglas, J. F., Sanders, K. B., Benneyworth, M. H., Smith, J. L., DeJean, V. M., McGrew, S. G., & Veenstra-VanderWeele, J. M. (2012) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-012-1661-2 · Cited by 30
“Medication treatment is primarily focused on relieving these comorbid symptoms (McPheeters et al. 2011).”
BackgroundSelf-citationAnagnostou, E. A., & Hansen, R. L. (2011) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e32834cba3e · Cited by 40
Malek, M., Ashraf‐Ganjouei, A., Moradi, K., Bagheri, S., Mohammadi, M.-R., & Akhondzadeh, S. (2020) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000382 · Cited by 33
“Further studies with larger sample sizes might be able to classify regressive ASD patients based on their inflammatory cytokine profile and suggest the effectiveness of corticosteroids in a particular subgroup of patients with regressive ASD.”
BackgroundInfluentialSchwenck, C., & Freitag, C. M. (2014) · ADHD Attention Deficit and Hyperactivity Disorders · doi:10.1007/s12402-014-0147-9 · Cited by 34
Treatment effectiveness for offenders with autism spectrum conditions: a systematic review
Melvin, C. L., Langdon, P. E., & Murphy, G. H. (2017) · Psychology Crime and Law · doi:10.1080/1068316x.2017.1324027 · Cited by 37
Psychopharmacology of Autism Spectrum Disorder
Siegel, M. (2012) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2012.07.006 · Cited by 27
Embryonic stem cell transplants as a therapeutic strategy in a rodent model of autism
Donegan, J. J., Boley, A. M., & Lodge, D. J. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0021-0 · Cited by 32
Moderate Effects of Low-Intensity Behavioral Intervention
Lotfizadeh, A. D., Kazemi, E., Pompa-Craven, P., & Eldevik, S. (2018) · Behavior Modification · doi:10.1177/0145445518796204 · Cited by 34
“The VABS (I and II) is one of the most widely used and validated assessment tools in ASD research (Stolte, Hodgetts, & Smith, 2016).”
BackgroundInfluentialPopow, C., Ohmann, S., & Plener, P. L. (2021) · Neuropsychiatrie · doi:10.1007/s40211-021-00395-9 · Cited by 36
Pervin, M. M., Ahmed, H. U., & Hagmayer, Y. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.834783 · Cited by 40
“(108) 2011 Medical treatments X X X X X (Iran) 18 0 10 X Review specific AHQR standards (109)”
BackgroundErridge, S., Kerr‐Gaffney, J., Holvey, C., Coomber, R., Barros, D. A. R., Bhoskar, U., Mwimba, G., Praveen, K., Symeon, C., Sachdeva-Mohan, S., et al. (2022) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253221116240 · Cited by 31
Psychopharmacology of autism spectrum disorders: A selective review
Mohiuddin, S. S., & Ghaziuddin, M. (2012) · Autism · doi:10.1177/1362361312453776 · Cited by 35
“The main finding of this review is that despite the common use of medications in persons with ASD, few controlled studies have been undertaken, consistent with the findings of other reviews on this topic (Dinca et al., 2005; McPheeters et al., 2011).”
ResultNanjappa, M. S., Voyiaziakis, E., Pradhan, B., & Thippaiah, S. M. (2020) · CNS Spectrums · doi:10.1017/s109285292000214x · Cited by 30
“However, sometimes side effects from these medication classes can pose clinical challenges such as behavioral activation from the SSRIs, and metabolic syndrome, dyskinesias, and arrhythmias from antipsychotics such as risperidone and aripiprazole.(15) Therefore, it is important to have additional pharmacologic options…”
BackgroundHendren, R. L. (2013) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2013.03.002 · Cited by 34
Aripiprazole for Sexually Inappropriate Vocalizations in Frontotemporal Dementia
Reeves, R. R., & Perry, C. L. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000426190.64916.3b · Cited by 26
Keim, S. A., Jude, A., Smith, K., Khan, A. Q., Coury, D. L., Rausch, J. R., Udaipuria, S., Norris, M. N., Bartram, L. R., Narayanan, A. R., et al. (2022) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-021-05396-9 · Cited by 23
“Atypical antipsychotics are commonly prescribed for irritability with ASD, but side effects are significant, common, and of particular concern for young children (McPheeters et al., 2011).”
BackgroundJiang, S., Xiao, L., Sun, Y., He, M., Gao, C., Zhu, C., Chang, H., Ding, J., Li, W., Wang, Y., et al. (2022) · Molecular Medicine Reports · doi:10.3892/mmr.2022.12670 · Cited by 23
Translating the Rosetta Stone of N-Acetylcysteine
Dean, O. M., Bush, A. I., & Berk, M. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.04.001 · Cited by 26
Russell, G., Starr, S., Elphick, C., Rodogno, R., & Singh, I. (2018) · Health Expectations · doi:10.1111/hex.12637 · Cited by 23
Preoperative Evaluation, Premedication, and Induction of Anesthesia
Ghazal, E. A., Vadi, M. G., Mason, L. J., & Coté, C. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-42974-0.00004-5 · Cited by 30
Ishitobi, M., Hiratani, M., Kosaka, H., Takahashi, T., Mizuno, T., Asano, M., Murata, T., Tomoda, A., & Wada, Y. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.12.015 · Cited by 23
“Various psychotropic medications are currently used to treat a range of symptoms associated with PDD, including aggression, repetitive behaviors, low tolerance for frustration, and hyperactivity (McPheeters et al., 2011).”
BackgroundTherapeutic approaches for shankopathies
Wang, X., Bey, A. L., Chung, L., Krystal, A. D., & Jiang, Y. (2013) · Developmental Neurobiology · doi:10.1002/dneu.22084 · Cited by 27
“…behavioral analysis (ABA), early start denver model (ESDM), and treatment and education of autistic and related communication handicapped children (TEACCH) (Myers and Johnson, 2007; Dawson et al., 2010; Kasari and Lawton, 2010; McPheeters et al., 2011; Warren et al., 2011; Taylor et al., 2012).”
BackgroundInfluentialExtracting autism spectrum disorder data from the electronic health record
Connelly, C. D., Pérez, A., Barlow, H., Chiang, G. J., & Bush, R. A. (2017) · Applied Clinical Informatics · doi:10.4338/aci-2017-02-ra-0029 · Cited by 23
“Such data is critical if medical intervention for ASD is to be studied and to have sufficient strength of evidence to evaluate either their potential benefit or adverse effects [11] Data such as these will add to the growing body of clinical guidelines on the Agency for Healthcare Research and Quality (AHRQ) National…”
BackgroundLogan, S. L., Carpenter, L. A., Leslie, R. S., Hunt, K. S., Garrett-Mayer, E. S., Charles, J. M., & Nicholas, J. S. (2014) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-014-2156-0 · Cited by 29
Meymandi, M. S., Sepehri, G., Moslemizadeh, A., Shahrbabaki, S. S. V., & Bashiri, H. (2020) · International Journal of Developmental Neuroscience · doi:10.1002/jdn.10046 · Cited by 23
“…agents to treat the main symptoms of the autism spectrum disorder (ASD), and the atypical antipsychotic drugs especially risperidone and aripiprazole are the only recently approved drugs for the treatment of repetitive behaviors in children with ASDs (McPheeters et al., 2011; Owen et al., 2009).”
BackgroundSiu, A. M. H., Lin, Z., & Chung, J. (2019) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2019.04.006 · Cited by 26
Þorsteinsdóttir, S., Njarðvík, U., Bjarnason, R. G., Haraldsson, H., & Ólafsdóttir, A. S. (2021) · Appetite · doi:10.1016/j.appet.2021.105623 · Cited by 25
Gong, J., Jin, Z., Chen, H., He, J., Zhang, Y., & Yang, X. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114791 · Cited by 23
Amygdalar neurotransmission alterations in the BTBR mice model of idiopathic autism
Bové, M., Palmieri, M. A., Santoro, M., Agosti, L. P., Gaetani, S., Romano, A., Dimonte, S., Costantino, G., Sikora, V., Tucci, P., et al. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02905-z · Cited by 24
“Currently, there are no drugs approved to successfully treat ASD repetitive symptoms [19 – 22].”
The Role of Parvalbumin Interneurons in Autism Spectrum Disorder
Yao, Y., & Li, Q. (2024) · Journal of Neuroscience Research · doi:10.1002/jnr.25391 · Cited by 23
“Pharmacological therapies primarily target comorbid symptoms and often lead to serious associated adverse effects (McPheeters et al. 2011).”
Khanna, R., Jariwala, K., & West-Strum, D. S. (2012) · Journal of Intellectual Disability Research · doi:10.1111/j.1365-2788.2012.01563.x · Cited by 24
Özşahin, İ., Mustapha, M. T., Albarwary, S. A., Şanlıdağ, B., Ozsahin, D. U., & Butler, T. (2021) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2020-0162 · Cited by 22
The importance of autism research
Thurm, A. E., & Swedo, S. E. (2012) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2012.14.3/athurm · Cited by 31
Pregnancy in autistic women and social medical considerations: scoping review and meta- synthesis
Ferrara, R., Ricci, P., Damato, F. M., Iovino, L., Ricci, L., Cicinelli, G., Simeoli, R., & Keller, R. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1222127 · Cited by 28
Autism Spectrum Disorders in Iran
Mohammadi, M., Salmanian, M., & Akhondzadeh, S. (2011) · InTech eBooks · doi:10.5772/38965 · Cited by 11
“Nevertheless, several treatments have been performed to improve ASDs including behavioral, medical, biological, sensory- motor and relationship development interventions (17-21).”
BackgroundGholipour, K., Ghiasi, A., Shahrokhi, H., Dadashi, Z., Javanmard, S., Tabatabaei, S. H., & Iezadi, S. (2022) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-021-05388-9 · Cited by 27
“Children with autism spectrum disorders (ASD), which are considered severe developmental disabilities, are more likely to experience co-occurring conditions (McPheeters et al., 2011; Myers, 2009) such as other mental illnesses and medical problems, including intellectual disabilities (Elsabbagh et al.”
BackgroundAutism familiarity and knowledge among pharmacy students
Khanna, R., Jariwala, K., Holmes, E. R., & Ramachandran, S. (2013) · Currents in Pharmacy Teaching and Learning · doi:10.1016/j.cptl.2013.09.010 · Cited by 19
Current Practice and Future Avenues in Autism Therapy
Poustka, L., & Kamp‐Becker, I. (2016) · Current topics in behavioral neurosciences · doi:10.1007/7854_2016_442 · Cited by 19
Psychotropic Medications as Treatments for People with Autism Spectrum Disorder
Poling, A. D., Ehrhardt, K. E., & Li, A. (2017) · Autism and child psychopathology series · doi:10.1007/978-3-319-61738-1_25 · Cited by 21
Port, R. G., Berman, J., Liu, S., Featherstone, R. E., Roberts, T. P. L., & Siegel, S. J. (2019) · Brain Connectivity · doi:10.1089/brain.2018.0639 · Cited by 18
“There currently exists a range of behavioral interventions (Ospina et al., 2008), as well as dietary and pharmacological treatments (Masi et al., 2017; McPheeters et al., 2011), for the symptoms of ASD.”
BackgroundCalleja, S., Islam, A. F. M., Kingsley, J., & McDonald, R. L. (2019) · Medicine · doi:10.1097/md.0000000000014480 · Cited by 20
The use of antipsychotics in preschoolers: A veto or a sensible last option?
Memarzia, J., Tracy, D. K., & Giaroli, G. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881113519506 · Cited by 17
Brief Report: Autism Spectrum Disorder: A Comprehensive Survey of Randomized Controlled Trials
Tromans, S. J., & Adams, C. E. (2018) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-018-3569-y · Cited by 19
“Psychological and behavioural approaches are typically focussed on treating the core symptoms of ASD, whereas pharmacological treatments generally target frequently observed comorbid features, such as irritability, anxiety, hyperactivity and self-injurious behaviours (McPheeters et al. 2011).”
Zwilling, M., Romano, A., Hoffman, H., Lotan, M., & Tesler, R. (2022) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2022.948184 · Cited by 21
“Several forms of intervention have been proposed for reducing CB in people with ASD, including medications (Malone et al., 2005; Blankenship et al., 2010; McPheeters et al., 2011; Sawyer et al., 2014), behavioral interventions (Scotti et al.”
BackgroundAripiprazole for treating irritability in children & adolescents with autism: A systematic review
Ghanizadeh, A. J., Tordjman, S., & Jaafari, N. (2015) · The Indian Journal of Medical Research · doi:10.4103/0971-5916.166584 · Cited by 23
Solmi, M., Bodini, L., Cocozza, S., Seeman, M. V., Vieta, E., Dragioti, E., Carvalho, A. F., & Fusar‐Poli, P. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.09.635 · Cited by 17
Jiang, S., He, M., Xiao, L., Sun, Y., Ding, J., Li, W., Guo, B., Wang, L., Wang, Y., Gao, C., et al. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.835993 · Cited by 21
Bush, R. A., Stahmer, A. C., & Connelly, C. D. (2016) · Health Informatics Journal · doi:10.1177/1460458215581911 · Cited by 22
“(6) ASD is a complex health problem with significant comorbidities including intellectual disability, hyperactivity, and anxiety.(7) The presentation of ASD can vary widely among affected individuals and within an individual over the lifespan.”
BackgroundBehmanesh, H., Moghaddam, H. S., Mohammadi, M.-R., & Akhondzadeh, S. (2019) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000368 · Cited by 17
Nylander, L. (2013) · Springer eBooks · doi:10.1007/978-1-4614-4788-7_176 · Cited by 15
Ghaeli, P., Nikvarz, N., Alaghband‐Rad, J., Alimadadi, A., & Tehrani‐Doost, M. (2014) · Indian Journal of Psychological Medicine · doi:10.4103/0253-7176.127254 · Cited by 19
“Even though several studies have noted insignificant effects of risperidone on stereotypic behaviors of patients with autistic disorder,[5,23] several other studies have shown the effectiveness of risperidone in improving these behaviors.”
ResultCoury, D. L., Swedo, S. E., Thurm, A. E., Miller, D. T., Veenstra-VanderWeele, J. M., Carbone, P. S., & Taylor, J. L. (2014) · Current problems in pediatric and adolescent health care · doi:10.1016/j.cppeds.2013.12.002 · Cited by 20
Self-citationMontgomery, J. M., Martin, T. L., Shooshtari, S., Stoesz, B. M., Heinrichs, D. J., North, S., Dodson, L., Senkow, Q., & Douglas, J. (2014) · Exceptionality Education International · doi:10.5206/eei.v23i1.7701 · Cited by 21
“Although not the focus of this review, it is important to note that there are systematic reviews of psychopharmacology for children with ASD (e.g., McPheeters et al., 2011), where medications (e.g., atypical antipsychotic agents, stimulants, and serotonin-reuptake inhibitors) to reduce interfering…”
Pervin, M. M., & Hagmayer, Y. (2022) · Administration and Policy in Mental Health and Mental Health Services Research · doi:10.1007/s10488-022-01205-2 · Cited by 23
“, 2014, 2015) and the systematic review of medical treatments for children with ASD (McPheeters et al., 2011) was examined.”
BackgroundBlum, N. J. (2012) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/dbp.0b013e31823e05bb · Cited by 14
Gupta, N., & Gupta, M. (2023) · CNS Spectrums · doi:10.1017/s1092852923002389 · Cited by 18
“105 In contrast, most of the studies on MPH in individuals with ASD failed to distinguish between hyperactivity and irritability.”
ResultUnraveling the Spectrum: A Comprehensive Review of Autism Spectrum Disorder in India
Uke, P., Gaikwad, S. B., Vagha, K. J., & Wandile, S. (2024) · Cureus · doi:10.7759/cureus.62753 · Cited by 38
“Medications such as risperidone, aripiprazole (for maladaptive behaviors), methylphenidate, atomoxetine, clonidine, guanfacine (for ADHD), fluoxetine (for repetitive behaviors and rigidity), melatonin, and serotonin (for sleep disturbances) are some of the frequently used options [48].”
BackgroundPsychological Comorbidities in Autism Spectrum Disorder
Shaltout, E., Al-Dewik, N. I. E., Samara, M. M., Morsi, H. M., & Khattab, A. (2020) · Advances in neurobiology · doi:10.1007/978-3-030-30402-7_6 · Cited by 14
Unwanted Interactions Among Psychotropic Drugs and Other Treatments for Autism Spectrum Disorders
Theoharides, T. C., & Asadi, S. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31825e00e4 · Cited by 13
“Unauthorized reproduction of this article is prohibited. patents 7,906,153 and 12/861,152 (allowed) for treatment of neuroinflammatory conditions, as well as US patent applications No. 12/534,571 and No. 13/009,282 for the diagnosis and treatment of ASD.”
BackgroundInfluentialPark, J.-Y., Shin, S., Park, K. C., Jeong, E., & Park, J. H. (2016) · Journal of the Korean Chemical Society · doi:10.5012/jkcs.2016.60.2.125 · Cited by 13
Kiselev, Y., Handal, M., Hjellvik, V., Reichborn‐Kjennerud, T., Stoltenberg, C., Surén, P., Havdahl, A., & Skurtveit, S. O. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.596032 · Cited by 15
“There is a lack of evidence supporting the benefit of most psychotropic medications in children with ASD, while adverse drug effects are common (10, 12, 30, 31).”
BackgroundMiller, H. L., Thomi, M., Patterson, R. M., & Nandy, K. (2022) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-022-05604-0 · Cited by 13
“However, these medications have previously been shown to have a higher instance of adverse side effects in autistic children in comparison to typically-developing children (Antshel et al., 2016; McPheeters et al., 2011).”
Result
Metadata
- Authors
- McPheeters, M. L., Warren, Z., Sathe, N., Bruzek, J. L., Krishnaswami, S., Jerome, R. N., & Veenstra-VanderWeele, J.
- Affiliations
- Vanderbilt University (US)
- ORCID
- Venue
- Pediatrics
- Publisher
- American Academy of Pediatrics (AAP)
- Published
- 2011-05-01
- Volume
- 127
- Issue
- 5
- Pages
- e1312-e1321
- ISSN
- 0031-4005 (ISSN-L)
- 1098-4275
- OpenAlex
- W2121150539
- Cited by
- 356
- References
- 55
- Citations by year
- 2026: 4 · 2025: 18 · 2024: 16 · 2023: 16 · 2022: 19 · 2021: 17 · 2020: 23 · 2019: 22 · 2018: 27 · 2017: 28 · 2016: 20 · 2015: 28 · 2014: 25 · 2013: 42 · 2012: 41
- FWCI
- 3.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- PEDIATRICS (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Health Sciences › Medicine › Psychiatry and Mental health › Child Nutrition and Feeding Issues
- Social Sciences › Psychology › Developmental and Educational Psychology › Behavioral and Psychological Studies
- Keywords
- autism spectrum disorder, medical treatment, children, risperidone, aripiprazole, behavioral problems, repetitive behavior, adverse effects, serotonin reuptake inhibitors, stimulant medication, antipsychotic drugs, quality of evidence
- MeSH terms
- Aripiprazole, Child, Child Development Disorders, Pervasive, Child, Preschool, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Fluoxetine, Humans, Male, Patient Compliance, Piperazines, Prognosis, Serotonin Antagonists, Severity of Illness Index, Antipsychotic Agents, Citalopram, Quinolones, Randomized Controlled Trials as Topic, Treatment Outcome, Risperidone, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.